title: Use of the pentagastrin dog model to explore the food effects on formulations in early drug development.
abstract: The ability to extrapolate dosage performance from in vitro to in vivo situations has an important role in early drug development. In parallel, the Beagle dog has come to represent a useful animal model for extrapolation to humans especially when drugs formulated for humans are to be tested. In this article, the pentagastrin-induced Beagle dog model was validated internally to show that in the colony the dogs were generally responsive to known doses of pentagastrin that produces effects similar to gastrin in the stomach, i.e., increasing gastric acid production and lowering gastric pH. The effect was observed with a short time course, maximum pH lowering was observed between 0.5 and 1h with return to baseline at 2-4h. The dog stomach pH is a better representative of the human fasted stomach with this pretreatment. The ultimate goal was to use these animals in a food effect studies to predict the behavior of formulations in humans. The results for 4 compounds were provided in the dog and a clear relationship between the effect of food in the dog and the effect of food in humans was observed. While the directionality (positive or negative) of the effect could be adequately predicted, the extent of the effect could not be predicted for all the tested formulations of the 4 compounds. The data will be used to generate a database of known compounds from which a correlation can be drawn to make future predictions using the pentagastrin dog model.
authors.affiliation: Sanofi US, 55 Corporate Drive, Bridgewater, NJ 08807, USA. Electronic address: patricia.zane@sanofi.com.
authors.forename: P
authors.initials: P
authors.lastname: Zane
authors.affiliation: Sanofi US, 55 Corporate Drive, Bridgewater, NJ 08807, USA.
authors.forename: Z
authors.initials: Z
authors.lastname: Guo
authors.affiliation: Sanofi US, 55 Corporate Drive, Bridgewater, NJ 08807, USA.
authors.forename: D
authors.initials: D
authors.lastname: MacGerorge
authors.affiliation: Sanofi Recherche, 3, digue d'Alfortville, Bâtiment Claude Bernard, 94140 Alfortville, France.
authors.forename: P
authors.initials: P
authors.lastname: Vicat
authors.affiliation: Sanofi Recherche, 371, Rue du P. Blayac, 34184 Montpellier, France.
authors.forename: C
authors.initials: C
authors.lastname: Ollier
mesh_terms: D000284:Administration, Oral; D000818:Animals; D019540:Area Under Curve; D004285:Dogs; D005215:Fasting / Q000378:metabolism*; D018565:Food-Drug Interactions; D005744:Gastric Acid / Q000378:metabolism; D005746:Gastric Emptying / Q000187:drug effects; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D023421:Models, Animal; D010418:Pentagastrin / Q000008:administration & dosage*; D004364:Pharmaceutical Preparations / Q000008:administration & dosage / Q000097:blood / Q000737:chemistry / Q000378:metabolism*; D010599:Pharmacokinetics; D015203:Reproducibility of Results; D013045:Species Specificity
chemical_list: D004364:Pharmaceutical Preparations; D010418:Pentagastrin
keywords: Dog; Food effect; Pentagastrin; Pharmacokinetics